绥美凯治疗效果

It is a drug for the treatment of AIDS. It is currently the only three-in-one compound drug containing dolutegravir (DTG). So what is the therapeutic effect of Suimeikai?

The four outstanding advantages of Suimeikai (alias: Dotiabalamid Tablets) are:

1. Excellent curative effect and significant virus suppression effect;

2. The three drugs are perfectly equivalent, and both newly treated and previously treated patients have high drug resistance barriers, making it unlikely to lead to drug resistance;

3. It is easy to take, only needs to be taken once a day, and there is no need to consider food effects;

4. The drug has low side effects, is well tolerated, and has a low discontinuation rate due to drug side effects;

5. Metabolic pathways have few interactions with other drugs.

Judging from a large number of clinical trial data, DTG has a low discontinuation rate due to adverse reactions (ADR), which is 0.5%. The ADR decreases significantly after one year of taking the drug. The most common adverse reactions are gastrointestinal dysfunction, mental disorders and neurological disorders, but the adverse reaction rates are less than 1.5%. From the comparison with patients who failed the first-line regimen of RAL (Ascent) and EVG (Evitegravir), the other two integrase inhibitors, the number of drug-resistant mutations in Trimeq is significantly less than that of the other two drugs, making it less likely to develop drug resistance. In the real world, antiviral treatment-naïve patients treated with DTG have a lower proportion of central nervous system-related (CNS) adverse events than the four drugs RAL (Ascent), DRV/r (darunavir), EFV (efavirenz) and ATV/r (atazanavir). Therefore, the drug safety and effectiveness of Suimeike, which is based on DTG integrase inhibitors, is controllable.

Existing research shows that one year (48 weeks) after HIV infection treatment, 93% of infected people's viral load becomes negative.

Recommended related hot articles: /newsDetail/71938.html